EIF2AK3 and hepatocellular carcinoma: Sorafenib has been reported to inhibit system xc(‐), a pivotal component of cellular antioxidant systems.[29, 30] Consequently, we sought to investigate whether such a mechanism is also responsible for PERK‐mediated TRIB3 upregulation in hepatoma cells following sorafenib treatment.